B&L launches Stellaris Vision Enhancement System

Article

Bausch & Lomb (B&L) today launched its new Stellaris Vision Enhancement system, further demonstrating its dedication to its microincision cataract surgery franchise.

Bausch & Lomb (B&L) today launched its new Stellaris Vision Enhancement system, further demonstrating its dedication to its microincision cataract surgery franchise.

Following on from the successes of the Millennium Microsurgical System and the Akreos acrylic intraocular lenses (IOLs), Stellaris offers surgeons the opportunity to perform both biaxial and coaxial microincision cataract surgery (B-MICS and C-MICS, respectively) procedures through a 1.8 mm incision.

According to the firm, the Stellaris EQ fluidics management technology allows surgeons to choose either a flow-vacuum module (AFM) or an advanced vacuum module (AVM). It also allows them to switch between the two for greater flexibility, stability and efficiency.

Additional features include the new ergonomically-designed, six-crystal phaco handpiece, Bluetooth wireless-enabled dual-linear foot pedal, and high-definition touch-screen display.

"With the launch of the Stellaris Vision Enhancement System and our Akreos MI60 microincision lens, we are poised to further enhance our leadership position," said Alan Farnsworth, B&L corporate senior vice president and president, Europe, Middle East and Africa Region.

According to H. Burkhard Dick, MD of Universitäts-Augenklinik, Center for Vision Science, Ruhr University, Germany, who has used the Stellaris system in more than 50 cases, it offers good performance, control and versatility. Meanwhile, he feels the optimized cutting deals with even the hardest nuclei whilst the improved fluidics contribute greatly to chamber stability when performing both biaxial and microcoaxial phaco.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.